Patents by Inventor Eberhard Schneider

Eberhard Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20240115745
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid, Xaa7 is a residue of an amino thiol or an amino acid of formula, Yc is a cyclization element which is either present or absent, and the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 11, 2024
    Inventors: Frank OSTERKAMP, Christian HAASE, Eberhard SCHNEIDER, Jonas PROKSCH, Dirk ZBORALSKI, Matthias PASCHKE, Christiane SMERLING, Ulrich REINEKE
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20230212549
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X)
    Type: Application
    Filed: January 7, 2022
    Publication date: July 6, 2023
    Applicant: 3B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWIß, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK, Jan Lennart von Hacht
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20220315554
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X)
    Type: Application
    Filed: July 8, 2020
    Publication date: October 6, 2022
    Applicant: 3B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWISS, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20220273831
    Abstract: The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 1, 2022
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWISS, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK
  • TFPI inhibitors and methods of use
    Patent number: 11001613
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 11, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Peptide and peptidomimetic inhibitors
    Patent number: 10272132
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 30, 2019
    Assignee: Ra Pharmaceuticals, Inc.
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Hoarty, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
    Publication number: 20180256672
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 13, 2018
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Hoarty, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • Peptide and peptidomimetic inhibitors
    Patent number: 9999650
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 19, 2018
    Assignee: Ra Pharmaceuticals, Inc.
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Hoarty, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20180072784
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Application
    Filed: August 18, 2017
    Publication date: March 15, 2018
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael DOCKAL, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • TFPI inhibitors and methods of use
    Patent number: 9777051
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 3, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
    Publication number: 20170189470
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 6, 2017
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Hoarty, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • Peptide and peptidomimetic inhibitors
    Patent number: 9644004
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 9, 2017
    Assignee: Ra Pharmaceuticals, Inc.
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Arata, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
    Publication number: 20160083430
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Application
    Filed: December 8, 2015
    Publication date: March 24, 2016
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Arata, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • Methods for Purifying Pertussis Toxin and Peptides Useful Therefor
    Publication number: 20160032258
    Abstract: The present invention relates to reagents and methods for purifying pertussis toxin (PT).
    Type: Application
    Filed: April 6, 2015
    Publication date: February 4, 2016
    Applicant: SANOFI PASTEUR LIMITED
    Inventors: Andreas Jungbluth, Eberhard Schneider, Peter Wagner
  • Peptide and peptidomimetic inhibitors
    Patent number: 9238676
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 19, 2016
    Assignee: RA PHARMACEUTICALS, INC.
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Arata, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • Methods for purifying pertussis toxin and peptides useful therefor
    Patent number: 9145445
    Abstract: The present invention relates to reagents and methods for purifying pertussis toxin (PT).
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: September 29, 2015
    Assignee: SANOFI PASTEUR
    Inventors: Andreas Jungbluth, Eberhard Schneider, Peter Wagner
  • PEPTIDE AND PEPTIDOMIMETIC INHIBITORS
    Publication number: 20150166606
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 18, 2015
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Arata, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • Methods for Purifying Pertussis Toxin and Peptides Useful Therefor
    Publication number: 20140187742
    Abstract: The present invention relates to reagents and methods for purifying pertussis toxin (PT).
    Type: Application
    Filed: July 30, 2012
    Publication date: July 3, 2014
    Inventors: Andreas Jungbluth, Eberhard Schneider, Peter Wagner
  • TFPI inhibitors and methods of use
    Patent number: 8466108
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: June 18, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • PMMA binding peptides
    Patent number: 8455614
    Abstract: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: June 4, 2013
    Assignee: E.I. du Pont de Nemours and Company
    Inventors: Eberhard Schneider, Gregor Schurmann, Peter Wagner, Hong Wang